Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter Pylori in functional dyspepsia

Mureşan, I; Pop, Lucian Liviu; Dumitraşcu, Dan L.

doi:10.15386/mpr-1375

Cited by 12 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The symptoms of satiety, bloating, pain, and anxiety score changes in the two groups had no statistical significance. L. reuteri may be a good alternative to antibiotics, and it can be used to eradicate H. pylori infection in patients with chronic dyspepsia (Muresan et al 2019). However, Dore et al studied that the cure rate of taking PPI with Lactobacillus reuterii instead of antibiotics or bismuth was 12% (Dore et al 2019a).…”

Section: Probiotics With Ppimentioning

confidence: 99%

The impacts of probiotics in eradication therapy of Helicobacter pylori

Bai

Zhu

et al. 2022

Arch Microbiol

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a well-known pathogen that infects approximately half of the world’s population. It is a pathogenic agent with potential health hazards related to diverse diseases, especially digestive diseases, such as chronic gastritis, peptic ulcer, and gastric carcinoma. In clinical, antibiotics are commonly applied in eradication therapy of H. pylori. However, the increase in antibiotic resistance and side effects has induced the failure of eradication therapy. Recent studies have shown that probiotic supplementation has promising application prospects. It can restore the gastrointestinal microbiota balance and prevent dysbacteriosis caused by antibiotics. Furthermore, it has been reported to have direct or indirect inhibitory effects on H. pylori. Probiotics may have a beneficial effect on H. pylori eradication. However, the strain, dosages, duration times, and safety of probiotic supplementation need further study before clinical applications.

show abstract

Section: Probiotics With Ppimentioning

confidence: 99%

The impacts of probiotics in eradication therapy of Helicobacter pylori

Bai

Zhu

et al. 2022

Arch Microbiol

View full text Add to dashboard Cite

show abstract

“…This L. reuteri strain was shown to significantly decrease the HP bacterial load in infected adults in two weeks, suggesting that it might be used as an adhesion blocker in anti-HP therapies [ 41 ]. In a randomized trial in 46 patients, Muresan et al showed that triple therapy with Pantoprazole for 30 days associated with Amoxicillin, and Clarithromycin for 14 days, was comparable with a regimen of Pantoprazole plus L. reuteri DSMZ 17648 twice a day for 8 weeks with a better trend in favor of the antibiotic group as compared to the probiotic group (74% vs. 65%, respectively) [ 42 ]. Buckley et al concluded that L. reuteri DSM 17648 reduces H. pylori load, improving gastrointestinal symptoms in subjects positive to this infection, and improving antibiotic–gastrointestinal adverse effects that are common after eradication treatment with antibiotics [ 43 ].…”

Section: Use Of Different Strains Rather Than L Reuteri 17938 Against Hp Infection Without Antibioticsmentioning

confidence: 99%

Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection

Dargenio

Bizzoco

et al. 2021

Medicina

View full text Add to dashboard Cite

Helicobacter pylori (HP) is a Gram-negative bacterium which finds its suitable habitat in the stomach. The infection affects about half of the global population with high variability in prevalence among regions and for age. HP is the main causative agent of chronic active gastritis, peptic and duodenal ulcers, and may be the primary cause of gastric cancer or MALT lymphoma. Due to the high rate of failure of eradication therapy in various countries and the increase in antibiotic resistance reported in the literature, there is an ever wider need to seek alternative therapeutic treatments. Probiotics seem to be a promising solution. In particular, the Limosilactobacillus reuteri (L. reuteri) species is a Gram-positive bacterium and is commonly found in the microbiota of mammals. L. reuteri is able to survive the gastric acid environment and bile and to colonize the gastric mucosa. This species is able to inhibit the growth of several pathogenic bacteria through different mechanisms, keeping the homeostasis of the microbiota. In particular, it is able to secrete reuterin and reutericycline, substances that exhibit antimicrobial properties, among other molecules. Through the secretion of these and the formation of the biofilm, it has been found to strongly inhibit the growth of HP and, at higher concentrations, to kill it. Moreover, it reduces the expression of HP virulence factors. In clinical trials, L. reuteri has been shown to decrease HP load when used as a single treatment, but has not achieved statistical significance in curing infected patients. As an adjuvant of standard regimens with antibiotics and pump inhibitors, L. reuteri can be used not only to improve cure rates, but especially to decrease gastrointestinal symptoms, which are a common cause of lack of compliance and interruption of therapy, leading to new antibiotic resistance.

show abstract

“…However, these results are based on a small number of patients with FD (n = 20) (Table 1). A more recent study 47 has investigated the efficacy of L. reuteri DSMZ 17648 (Pylopass, Remedia Laboratories, Romania) twice a day plus pantoprazole 40 mg bid for 8 weeks versus triple therapy (pantoprazole 40 mg bid 30 days, amoxicillin 1000 mg bid 14 days, and clarithromycin 500 mg bid 14 days) in FD patients Hp positive. Results support the use of probiotics since eradication of Hp was associated with improvement of dyspeptic symptoms and anxiety score in both subgroups.…”

Section: Clinical Trials That Used Probiotics In Patients With Fdmentioning

confidence: 99%